Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers

Table 5

90% Confidence intervals of 𝐶max, AUC0−𝑡, and AUC0−∞ from the fed condition compared to the fasted conditions for the test product and reference product.

Pharmacokinetic parameter	90% Confidence interval
	Test product; (Glycon MR)	Reference product; (Diamicron MR)
𝐶max; AUC0−𝑡; AUC0−∞	0.93–1.09; 0.81–1.00; 0.80–1.01	0.94–1.14; 0.90–1.08; 0.91–1.10

Bioequivalence interpretation requires the 90% confidence intervals to be within the acceptance criteria of 0.8–1.25.